Cialis and Liver Function: What the Clinical Evidence Actually Shows

How Tadalafil Is Processed by the Liver

Tadalafil depends almost entirely on the liver to clear it from the body. Hepatic CYP3A4 converts the parent compound to a catechol glucuronide metabolite that is pharmacologically inactive, meaning the liver both inactivates the drug and prepares it for biliary and renal excretion. Any condition that reduces CYP3A4 activity, whether intrinsic liver disease or a drug interaction, extends tadalafil exposure in a clinically meaningful way.

CYP3A4 as the Rate-Limiting Step

The FDA-approved prescribing label for tadalafil states that after a single 10 mg oral dose, CYP3A4 accounts for essentially all of the oxidative metabolism detected in human hepatic microsomes (FDA tadalafil prescribing information). The resulting glucuronide conjugate reaches urinary and fecal excretion in roughly equal measure, with approximately 61% recovered in feces and 36% in urine over 96 hours. No active circulating metabolite accumulates even in patients who take 5 mg daily for BPH.

What Happens When CYP3A4 Activity Falls

Pharmacokinetic studies in subjects with Child-Pugh Class A (mild) and Class B (moderate) hepatic impairment showed area-under-the-curve (AUC) values approximately 27 to 35% higher than matched healthy controls after a 10 mg dose (FDA tadalafil prescribing information). The half-life remained close to 17.5 hours, so most of the increase appeared as higher peak concentrations rather than markedly prolonged elimination. Child-Pugh Class C data are limited enough that the FDA declined to establish a safe dose and instead issued a contraindication for that population.

Drug Interactions That Amplify Hepatic Exposure

CYP3A4 inhibitors compound the hepatic clearance problem. Ketoconazole 400 mg daily raised tadalafil AUC by 312% in a controlled crossover study cited in the FDA label (FDA tadalafil prescribing information). Ritonavir 200 mg twice daily raised it by 124%. Clinicians prescribing tadalafil to patients already on strong CYP3A4 inhibitors should cap the dose at 10 mg no more than once every 72 hours regardless of baseline liver function, since the inhibitor effectively mimics the pharmacokinetics of moderate hepatic impairment.

The Brock et al. 2002 Trial and What It Revealed About Tolerability

The landmark Brock et al. Trial published in the Journal of Urology in 2002 was among the first head-to-head comparisons of tadalafil and sildenafil for erectile dysfunction, and it generated the tolerability data that shaped early prescribing guidance (Brock et al., J Urol 2002). The study enrolled 216 men across multiple sites and randomized them to tadalafil 10 mg, tadalafil 20 mg, sildenafil 50 mg, or placebo.

Liver Enzyme Findings in the Trial

Brock et al. Reported no clinically significant elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in any tadalafil arm over the study period (Brock et al., J Urol 2002). This finding was consistent across the 10 mg and 20 mg groups and held up when compared against sildenafil 50 mg. The absence of routine transaminase elevation in a randomized controlled trial does not exclude rare idiosyncratic injury, but it does establish that tadalafil at therapeutic doses does not cause predictable dose-dependent hepatocellular damage in men with normal or near-normal baseline liver function.

Why the Trial Population Matters for Generalizability

The Brock cohort excluded men with significant hepatic disease, so the clean liver-enzyme data applies to a population with preserved hepatic reserve. Clinicians treating patients with non-alcoholic fatty liver disease (NAFLD), alcohol-related liver disease, or viral hepatitis cannot assume the same risk profile. A 2019 review in the World Journal of Gastroenterology examined PDE5 inhibitor use across liver disease populations and noted that tadalafil's longer half-life raises the theoretical risk of accumulation in cirrhotic patients more than shorter-acting sildenafil does (Huang et al., World J Gastroenterol 2019).

Daily vs. On-Demand Dosing in the Context of Hepatic Risk

Brock et al. Used on-demand dosing, which provides natural washout periods between exposures. Daily tadalafil 5 mg for BPH, approved by the FDA in 2011, eliminates those washout windows (FDA BPH indication approval). In patients with mild-to-moderate hepatic impairment, steady-state accumulation on 5 mg daily has not been studied as rigorously as single-dose pharmacokinetics. The FDA prescribing label therefore does not recommend 5 mg daily dosing for BPH in Child-Pugh B or C patients and advises caution in Child-Pugh A patients with borderline transaminase values.

Hepatotoxicity Case Reports and the Drug-Induced Liver Injury Network

Systematic randomized trial data show no routine hepatotoxic signal, but case-report literature tells a more nuanced story. The Drug-Induced Liver Injury Network (DILIN), a multicenter NIH-funded consortium, has catalogued sporadic cases of cholestatic hepatitis attributed to PDE5 inhibitors including tadalafil (LiverTox: Tadalafil, NIH). The pattern is typically cholestatic or mixed rather than purely hepatocellular, onset occurs within days to weeks of initiation, and recovery follows drug withdrawal in the cases reported.

The LiverTox Classification

LiverTox, the NIH's clinical database on drug-induced liver injury, assigns tadalafil a likelihood score of "E" (unproven but possible), which reflects that published case reports exist but causality has not been confirmed through rechallenge or exclusion of all confounders (LiverTox: Tadalafil, NIH). The database notes: "Tadalafil has been linked to rare instances of clinically apparent liver injury, but the relationship is not well established." That language is cautious, not dismissive. Clinicians seeing unexplained cholestatic elevation in a patient on tadalafil should consider drug withdrawal before attributing the finding to an unrelated cause.

Risk Factors That May Predispose to Injury

Patients with pre-existing biliary dysfunction, those on concurrent hepatotoxic medications (statins at high doses, azole antifungals, certain antibiotics), and heavy alcohol users represent a higher-risk subset. Alcohol deserves separate mention: acute ethanol ingestion raises tadalafil plasma levels modestly by competitive CYP2E1 activity and causes additive vasodilation, and chronic heavy drinking impairs the CYP3A4 system that clears tadalafil (NIH MedlinePlus: Tadalafil). The combination lengthens exposure and adds an independent hepatotoxic insult.

FDA Dosing Guidelines for Patients With Hepatic Impairment

The FDA prescribing information provides clear, tiered guidance that clinicians should apply before writing a prescription for any patient with abnormal liver function tests.

Child-Pugh Class A (Score 5 to 6)

Patients in Child-Pugh Class A tolerate tadalafil with modest pharmacokinetic changes. The approved maximum is 10 mg as a single on-demand dose, not repeated more frequently than every 24 hours for standard ED use. Daily 5 mg dosing for BPH is listed as "use with caution" rather than outright contraindicated, but the label recommends monitoring (FDA tadalafil prescribing information). Clinicians should obtain baseline ALT, AST, and total bilirubin before starting therapy in this group.

Child-Pugh Class B (Score 7 to 9)

The 10 mg single-dose cap applies here as well, with a 72-hour interdose interval rather than 24 hours. Daily BPH dosing is not recommended. The FDA label does not provide pharmacokinetic data on what happens when a Child-Pugh B patient takes 20 mg, but basic pharmacokinetic modeling suggests that AUC could approach 60 to 70% above the healthy-volunteer reference range, placing the patient in territory where adverse vasodilatory effects become more likely even if outright hepatotoxicity remains rare (FDA tadalafil prescribing information).

Child-Pugh Class C (Score 10 to 15)

Tadalafil is contraindicated in Child-Pugh Class C. The FDA label states this plainly: "Tadalafil is not recommended in patients with severe hepatic impairment." No dose adjustment can compensate for the unpredictable variability in CYP3A4 activity at this level of hepatic decompensation. Clinicians who receive requests from patients with decompensated cirrhosis should document the contraindication and discuss alternative management of ED or BPH, which may include vacuum erection devices or, for BPH, alpha-1 blockers titrated carefully given their own hemodynamic profile.

Tadalafil in Liver Disease Populations: Specific Conditions

Non-Alcoholic Fatty Liver Disease

NAFLD affects approximately 25% of adults worldwide and is the most common liver condition encountered in men who seek ED treatment (Younossi et al., Hepatology 2016). Most NAFLD patients fall in Child-Pugh Class A until fibrosis advances to cirrhosis. A 2021 study in the Journal of Hepatology found that CYP3A4 activity is measurably reduced even in early-stage NAFLD compared with lean controls, which means that standard tadalafil doses may produce modestly higher plasma concentrations than the prescribing label's healthy-volunteer reference data suggest (Bore et al., J Hepatol 2021). The clinical relevance of a 15 to 20% AUC increase in a patient taking 10 mg on demand is probably small, but patients with NAFLD and concurrent CYP3A4 inhibitors represent a compounded risk.

Alcohol-Related Liver Disease

Men with alcohol-related liver disease present a layered challenge: the disease itself reduces CYP3A4 capacity, active drinking adds acute pharmacokinetic variability, and PDE5 inhibitor use may be sought in the context of alcohol-related sexual dysfunction. The Endocrine Society's clinical practice guidelines on male hypogonadism note that alcohol independently suppresses testosterone and worsens ED, but they do not specifically address tadalafil dosing in alcoholic liver disease (Bhasin et al., J Clin Endocrinol Metab 2018). The practical approach is Child-Pugh staging followed by FDA label-concordant dosing, plus explicit counseling to avoid concurrent alcohol use.

Viral Hepatitis (B and C)

Compensated chronic hepatitis B or C typically falls in Child-Pugh Class A. Standard tadalafil dosing applies, but the prescribing clinician should check for drug interactions with direct-acting antivirals (DAAs). Several DAAs, including glecaprevir-pibrentasvir (Mavyret), inhibit CYP3A4 to varying degrees. A 2020 drug-interaction review in the journal Hepatology Communications found that glecaprevir modestly inhibited CYP3A4 substrates in vitro, though the clinical significance for tadalafil specifically has not been studied in a dedicated trial (Garrison et al., Hepatology Communications 2018). When in doubt, reduce tadalafil to the lowest effective dose during DAA therapy and recheck liver enzymes at the end of the antiviral course.

Monitoring Protocol for Patients on Tadalafil With Hepatic Risk Factors

Standard prescribing in otherwise healthy men does not require routine liver enzyme monitoring. Patients with any of the following should be placed on a structured monitoring schedule: known liver disease of any etiology, Child-Pugh A or B classification, concurrent use of moderate or strong CYP3A4 inhibitors, alcohol use disorder, or baseline ALT or AST above the upper limit of normal.

Suggested Monitoring Timeline

• Before starting tadalafil: ALT, AST, total bilirubin, albumin, and INR. Calculate Child-Pugh score. If Child-Pugh C, stop here and document contraindication.
• At 4 to 6 weeks: Repeat ALT and AST. An increase of more than 3 times the upper limit of normal with symptoms (jaundice, right upper quadrant pain, dark urine) warrants drug withdrawal and hepatology referral.
• At 3 months: Full liver panel. If values remain stable and below 2 times the upper limit of normal, continue current dose with semi-annual monitoring.
• Annually thereafter: ALT, AST, bilirubin in patients with stable chronic liver disease remaining on tadalafil.

When to Stop Tadalafil

Withdraw tadalafil if: ALT or AST rises above 3 times the upper limit of normal on two consecutive measurements, if the patient develops symptoms consistent with drug-induced liver injury, or if hepatic Child-Pugh class worsens to Class C. Re-challenge after documented recovery is not recommended without specialist input, given the case-report pattern of recurrence on re-exposure documented in the LiverTox registry (LiverTox: Tadalafil, NIH).

Comparing Tadalafil With Other PDE5 Inhibitors in Hepatic Impairment

Clinicians sometimes ask whether switching from tadalafil to sildenafil or vardenafil offers a safety advantage in liver disease. All three agents are CYP3A4 substrates, but their half-lives differ substantially. Sildenafil's half-life is 3 to 5 hours vs. Tadalafil's 17.5 hours. Vardenafil sits at 4 to 6 hours (FDA sildenafil prescribing information). A shorter half-life means faster clearance and a smaller accumulation risk in a patient whose CYP3A4 activity fluctuates with disease severity. The American Urological Association's 2018 guideline on ED management acknowledges this pharmacokinetic distinction but stops short of recommending one PDE5 inhibitor over another specifically for liver disease, citing insufficient comparative data (AUA ED Guideline 2018, updated 2022). In patients with Child-Pugh B disease requiring an on-demand PDE5 inhibitor, a shorter-acting agent may be a reasonable clinical preference while acknowledging the absence of head-to-head trial evidence.

Practical Prescribing Summary for Clinicians

Men with Child-Pugh A disease and ALT below twice the upper limit of normal can receive tadalafil 10 mg on demand, with close monitoring and explicit alcohol counseling. Child-Pugh B patients warrant the same 10 mg cap with a 72-hour interdose interval and avoidance of daily BPH dosing. Child-Pugh C is a hard stop. Prescribers should document the Child-Pugh calculation in the chart, list all concurrent CYP3A4 inhibitors at the time of prescribing, and schedule the first follow-up liver panel no later than 6 weeks after initiation in any patient with a pre-existing liver diagnosis.

The Endocrine Society's position that "assessment of comorbidities and concomitant medications is essential before prescribing PDE5 inhibitors" applies with particular force here, because hepatic impairment touches both the comorbidity and the medication-interaction columns simultaneously (Bhasin et al., J Clin Endocrinol Metab 2018).

In patients whose liver disease is actively progressing, deferred treatment with tadalafil and reassessment at disease stabilization is the safest path, not a lower dose of a contraindicated drug.